Cargando…

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015

BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Greulich, Timm, Nell, Christoph, Herr, Christian, Vogelmeier, Claus, Kotke, Viktor, Wiedmann, Stefan, Wencker, Marion, Bals, Robert, Koczulla, Andreas Rembert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901499/
https://www.ncbi.nlm.nih.gov/pubmed/27282198
http://dx.doi.org/10.1186/s13023-016-0453-8
_version_ 1782436817758322688
author Greulich, Timm
Nell, Christoph
Herr, Christian
Vogelmeier, Claus
Kotke, Viktor
Wiedmann, Stefan
Wencker, Marion
Bals, Robert
Koczulla, Andreas Rembert
author_facet Greulich, Timm
Nell, Christoph
Herr, Christian
Vogelmeier, Claus
Kotke, Viktor
Wiedmann, Stefan
Wencker, Marion
Bals, Robert
Koczulla, Andreas Rembert
author_sort Greulich, Timm
collection PubMed
description BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients. The present study provides an update on the results of our targeted screening program (German AAT laboratory, University of Marburg) covering a period from August 2003 to May 2015. METHODS: Diagnostic AATD detection test kits were offered free of charge. Dried blood samples were sent to our laboratory and used for the semiquantitative measurement of the AAT-level (nephelometry) and the detection of the S- or Z-allele (PCR). Isoelectric focusing was performed when either of the initial tests was indicative for at least one mutation. Besides, we evaluated the impact of additional screening efforts and the changes of the detection rate over time, and analysed the relevance of clinical parameters in the prediction of severe AATD. RESULTS: Between 2003 and 2015, 18,638 testing kits were analysed. 6919 (37.12 %) carried at least one mutation. Of those, we identified 1835 patients with severe AATD (9.82 % of the total test population) including 194 individuals with rare genotypes. Test initiatives offered to an unselected population resulted in a dramatically decreased detection rate. Among clinical characteristics, a history of COPD, emphysema, and bronchiectasis were significant predictors for Pi*ZZ, whereas a history of asthma, cough and phlegm were predictors of not carrying the genotype Pi*ZZ. CONCLUSION: A targeted screening program, combining measures to increase awareness with cost-free diagnostic testing, resulted in a high rate of AATD detection. The clinical data suggest that testing should be primarily offered to patients with COPD, emphysema, and/or bronchiectasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0453-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4901499
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49014992016-06-11 Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015 Greulich, Timm Nell, Christoph Herr, Christian Vogelmeier, Claus Kotke, Viktor Wiedmann, Stefan Wencker, Marion Bals, Robert Koczulla, Andreas Rembert Orphanet J Rare Dis Research BACKGROUND: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free diagnostic testing results in the detection of a relevant number of severely deficient AATD patients. The present study provides an update on the results of our targeted screening program (German AAT laboratory, University of Marburg) covering a period from August 2003 to May 2015. METHODS: Diagnostic AATD detection test kits were offered free of charge. Dried blood samples were sent to our laboratory and used for the semiquantitative measurement of the AAT-level (nephelometry) and the detection of the S- or Z-allele (PCR). Isoelectric focusing was performed when either of the initial tests was indicative for at least one mutation. Besides, we evaluated the impact of additional screening efforts and the changes of the detection rate over time, and analysed the relevance of clinical parameters in the prediction of severe AATD. RESULTS: Between 2003 and 2015, 18,638 testing kits were analysed. 6919 (37.12 %) carried at least one mutation. Of those, we identified 1835 patients with severe AATD (9.82 % of the total test population) including 194 individuals with rare genotypes. Test initiatives offered to an unselected population resulted in a dramatically decreased detection rate. Among clinical characteristics, a history of COPD, emphysema, and bronchiectasis were significant predictors for Pi*ZZ, whereas a history of asthma, cough and phlegm were predictors of not carrying the genotype Pi*ZZ. CONCLUSION: A targeted screening program, combining measures to increase awareness with cost-free diagnostic testing, resulted in a high rate of AATD detection. The clinical data suggest that testing should be primarily offered to patients with COPD, emphysema, and/or bronchiectasis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0453-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-10 /pmc/articles/PMC4901499/ /pubmed/27282198 http://dx.doi.org/10.1186/s13023-016-0453-8 Text en © Greulich et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Greulich, Timm
Nell, Christoph
Herr, Christian
Vogelmeier, Claus
Kotke, Viktor
Wiedmann, Stefan
Wencker, Marion
Bals, Robert
Koczulla, Andreas Rembert
Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title_full Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title_fullStr Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title_full_unstemmed Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title_short Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
title_sort results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901499/
https://www.ncbi.nlm.nih.gov/pubmed/27282198
http://dx.doi.org/10.1186/s13023-016-0453-8
work_keys_str_mv AT greulichtimm resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT nellchristoph resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT herrchristian resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT vogelmeierclaus resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT kotkeviktor resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT wiedmannstefan resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT wenckermarion resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT balsrobert resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015
AT koczullaandreasrembert resultsfromalargetargetedscreeningprogramforalpha1antitrypsindeficiency20032015